blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4013451

EP4013451 - METHODS FOR PREVENTING DENGUE AND HEPATITIS A [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  20.05.2022
Database last updated on 07.04.2026
FormerThe international publication has been made
Status updated on  26.02.2021
Formerunknown
Status updated on  24.04.2020
Most recent event   Tooltip21.03.2026New entry: Renewal fee paid 
Applicant(s)For all designated states
Takeda Vaccines, Inc.
75 Sidney Street
Cambridge, MA 02139 / US
[2022/25]
Inventor(s)01 / WALLACE, Derek
20 Adams Street
Brookline, Massachusetts 02446 / US
 [2022/25]
Representative(s)Maiwald GmbH
Elisenhof
Elisenstraße 3
80335 München / DE
[N/P]
Former [2022/25]Maiwald Patent- und Rechtsanwaltsgesellschaft mbH
Elisenhof
Elisenstraße 3
80335 München / DE
Application number, filing date20719243.604.03.2020
[2022/25]
WO2020US20991
Priority number, dateID2019000724116.08.2019         Original published format: ID 201907241
EP2019019569205.09.2019         Original published format: EP 19195692
US20191656195305.09.2019         Original published format: US201916561953
WO2019US4974905.09.2019         Original published format: PCT/US2019/049749
[2022/25]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2021034349
Date:25.02.2021
Language:EN
[2021/08]
Type: A1 Application with search report 
No.:EP4013451
Date:22.06.2022
Language:EN
The application published by WIPO in one of the EPO official languages on 25.02.2021 takes the place of the publication of the European patent application.
[2022/25]
Search report(s)International search report - published on:EP25.02.2021
ClassificationIPC:A61K39/295, A61K39/12, A61K39/00, A61K39/125, A61K39/29
[2022/25]
CPC:
A61K39/12 (EP,KR); A61K39/29 (KR); A61P31/14 (KR);
A61K2039/5252 (EP,KR); A61K2039/5254 (EP,KR); A61K2039/54 (KR);
A61K2039/545 (KR); A61K2039/55 (EP,KR); A61K2039/55505 (KR);
A61K2039/70 (EP,KR); C12N2770/24134 (EP,KR); C12N2770/32434 (EP,KR);
Y02A50/30 (EP) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2022/25]
TitleGerman:VERFAHREN ZUR VORBEUGUNG VON DENGUE UND HEPATITIS A[2022/25]
English:METHODS FOR PREVENTING DENGUE AND HEPATITIS A[2022/25]
French:MÉTHODE DE PRÉVENTION DE LA DENGUE ET DE L'HÉPATITE A[2022/25]
Entry into regional phase14.03.2022National basic fee paid 
14.03.2022Designation fee(s) paid 
14.03.2022Examination fee paid 
Examination procedure14.03.2022Examination requested  [2022/25]
14.03.2022Date on which the examining division has become responsible
13.12.2022Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time
13.12.2022Despatch of communication of loss of particular rights: Claims {1}
02.02.2023Amendment by applicant (claims and/or description)
Request for further processing for:Loss of rights: Claims
02.02.2023Request for further processing filed
02.02.2023Full payment received (date of receipt of payment)
Request granted
10.02.2023Decision despatched
02.02.2023Request for further processing filed
02.02.2023Full payment received (date of receipt of payment)
Request granted
10.02.2023Decision despatched
02.02.2023Request for further processing filed
02.02.2023Full payment received (date of receipt of payment)
Request granted
10.02.2023Decision despatched
Fees paidRenewal fee
14.03.2022Renewal fee patent year 03
22.03.2023Renewal fee patent year 04
20.03.2024Renewal fee patent year 05
19.03.2025Renewal fee patent year 06
19.03.2026Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[A] WO2014093182  (INVIRAGEN INC et al.)
 [Y]   ANONYMOUS: "Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Co-administered With an Hepatitis A Virus Vaccine", 15 May 2018 (2018-05-15), XP055519457, Retrieved from the Internet [retrieved on 20181026]
 [Y]   STEPHEN RINDERKNECHT ET AL: "Immunogenicity and Safety of an Inactivated Hepatitis A Vaccine When Coadministered With Measles-mumps-rubella and Varicella Vaccines in Children Less Than 2 Years of Age :", PEDIATRIC INFECTIOUS DISEASE JOURNAL., vol. 30, no. 10, 1 October 2011 (2011-10-01), US, pages e179 - e185, XP055517064, ISSN: 0891-3668, DOI: 10.1097/INF.0b013e31822256a5

DOI:   http://dx.doi.org/10.1097/INF.0b013e31822256a5
 [Y]   JORGE E OSORIO ET AL: "Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study", LANCET INFECTIOUS DISEASES, vol. 14, no. 9, 1 September 2014 (2014-09-01), US, pages 830 - 838, XP055517052, ISSN: 1473-3099, DOI: 10.1016/S1473-3099(14)70811-4

DOI:   http://dx.doi.org/10.1016/S1473-3099(14)70811-4
 [Y]   SARAH L. GEORGE ET AL: "Safety and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine Candidate in Flavivirus-Naive Adults: A Randomized, Double-Blinded Phase 1 Clinical Trial", JOURNAL OF INFECTIOUS DISEASES. JID, vol. 212, no. 7, 19 March 2015 (2015-03-19), US, pages 1032 - 1041, XP055517050, ISSN: 0022-1899, DOI: 10.1093/infdis/jiv179

DOI:   http://dx.doi.org/10.1093/infdis/jiv179
 [Y]   RICHARD RUPP ET AL: "Safety and immunogenicity of different doses and schedules of a live attenuated tetravalent dengue vaccine (TDV) in healthy adults: A Phase 1b randomized study", VACCINE, vol. 33, no. 46, 1 November 2015 (2015-11-01), AMSTERDAM, NL, pages 6351 - 6359, XP055517032, ISSN: 0264-410X, DOI: 10.1016/j.vaccine.2015.09.008

DOI:   http://dx.doi.org/10.1016/j.vaccine.2015.09.008
 [Y]   SEZ-LLORENS XAVIER ET AL: "Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study", LANCET INFECTIOUS DISEASES, ELSEVIER LTD, US, vol. 17, no. 6, 30 March 2017 (2017-03-30), pages 615 - 625, XP085037411, ISSN: 1473-3099, DOI: 10.1016/S1473-3099(17)30166-4

DOI:   http://dx.doi.org/10.1016/S1473-3099(17)30166-4
 [A]   ANONYMOUS: "WHO Recommendations for all immunization programmes", 1 August 2018 (2018-08-01), XP055519312, Retrieved from the Internet [retrieved on 20181026]
 [A]   KING GAIL E ET AL: "Simultaneous administration of childhood vaccines: An important public health policy that is safe and efficacious", PEDIATRIC INFECTIOUS DISEASE JOUR, LIPPINCOTT WILLIAMS & WILKINS, US, vol. 13, no. 5, 1 January 1994 (1994-01-01), pages 394 - 407, XP009134534, ISSN: 0891-3668, DOI: 10.1097/00006454-199405000-00012

DOI:   http://dx.doi.org/10.1097/00006454-199405000-00012
 [A]   CHOKEPHAIBULKIT KULKANYA: "COMBINATION VACCINES", CHOT MAI HET THANG PHAET - JOURNAL OF THE MEDICAL ASSOCIATION OF THAI, MEDICAL ASSOCIATION OF THAILAND, TH, vol. 85, no. SUPPL. 2, 1 August 2002 (2002-08-01), pages S694 - S699, XP009081511, ISSN: 0125-2208
 [A]   JORGE E. OSORIO ET AL: "A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone", EXPERT REVIEW OF VACCINES, vol. 15, no. 4, 2 April 2016 (2016-04-02), GB, pages 497 - 508, XP055517022, ISSN: 1476-0584, DOI: 10.1586/14760584.2016.1128328

DOI:   http://dx.doi.org/10.1586/14760584.2016.1128328
 [A]   LI-MIN HUANG ET AL: "Concomitant administration of live attenuated Japanese encephalitis chimeric virus vaccine (JE-CV) and measles, mumps, rubella (MMR) vaccine: Randomized study in toddlers in Taiwan", VACCINE, vol. 32, no. 41, 1 September 2014 (2014-09-01), AMSTERDAM, NL, pages 5363 - 5369, XP055517059, ISSN: 0264-410X, DOI: 10.1016/j.vaccine.2014.02.085

DOI:   http://dx.doi.org/10.1016/j.vaccine.2014.02.085
 [A]   JORGE E OSORIO ET AL: "Development of DENVax: A chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever", VACCINE, vol. 29, no. 42, 11 July 2011 (2011-07-11), pages 7251 - 7260, XP028285284, ISSN: 0264-410X, [retrieved on 20110711], DOI: 10.1016/J.VACCINE.2011.07.020

DOI:   http://dx.doi.org/10.1016/j.vaccine.2011.07.020
by applicantWO2018027075
 WO9837911
 WO03101397
 WO2007021672
 WO2008007021
 WO2008047023
 WO2008065315
 WO2016034629
 WO2008022196
   CAPEDING MR ET AL.: "Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial", LANCET, vol. 384, 2014, pages 1358 - 65, XP055532736, DOI: 10.1016/S0140-6736(14)61060-6

DOI:   http://dx.doi.org/10.1016/S0140-6736(14)61060-6
   VILLAR LA ET AL.: "Safety and immunogenicity of a recombinant tetravalent dengue vaccine in 9-16 year olds: a randomized, controlled, phase II trial in Latin America", PEDIATR INFECT DIS J, vol. 32, 2013, pages 1102 - 9
   SRIDHAR S ET AL.: "Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy", N ENGL J MED, vol. 379, 2018, pages 327 - 40
   "Wkly. Epidemiol. Rec.", vol. 93, September 2018, WORLD HEALTH ORGANIZATION, article "Dengue Vaccine: WHO position paper", pages: 457 - 476
   S.R. HADINEGORO ET AL.: "Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 373, pages 1195
   BHAMARAPRAVATI ET AL., BULLETIN OF THE WORLD HEALTH ORGANIZATION, vol. 65, no. 2, 1987, pages 189 - 195
   BHATT ET AL., NATURE, vol. 496, no. 7446, 2013, pages 504 - 507
   STANAWAY ET AL., LANCET INFECT DIS., vol. 16, no. 6, 2016, pages 712 - 723
   "the WHO Guidelines", 2007, DEPARTMENT OF IMMUNIZATION VACCINES BIOLOGICALS
   BECK ET AL., J TRAVEL MED, vol. 11, 2004, pages 201 - 207
   "Observed Rate of Vaccine Reactions - Hepatitis A Vaccine", WHO INFORMATION SHEET, June 2012 (2012-06-01)
   ANDRE FE.HEPBURN A.D'HONDT E.: "Inactivated candidate vaccines for hepatitis", A. PROG MED VIROL, vol. 37, 1990, pages 72 - 95
   MORRISON D ET AL., J INFECT DIS., vol. 201, no. 3, 2010, pages 370 - 7
   KINNEY ET AL., VIROLOGY, vol. 230, no. 2, 1997, pages 300 - 308
   BHAMARAPRAVATI ET AL., BULL. WORLD HEALTH ORGAN., vol. 65, no. 2, 1987, pages 189 - 195
   BUTRAPET ET AL., J. VIROL., vol. 74, no. 7, 2000, pages 3111 - 3119
   HUANG ET AL., J. VIROL., vol. 77, no. 21, 2003, pages 11436 - 11447
   COHEN ET AL., JOURNAL OF VIROLOGY, vol. 61, no. 1, January 1987 (1987-01-01), pages 50 - 59
   S.S. WHITEHEAD, EXPERT REV VACCINES, vol. 15, no. 4, 2016, pages 509 - 517
   J. VIROLOGY, vol. 77, no. 21, 2003, pages 11436 - 11447
   HUANG ET AL., PLOS NEGLECTED DIS, vol. 7, no. 5, 2013, pages e2243
   HENCHAL ET AL., AM. J. TROP. MED. HYG., vol. 31, no. 4, 1982, pages 830 - 555
   HENCHAL ET AL., AM. J. TROP. MED. HYG., vol. 34, 1985, pages 162 - 169
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.